Merck & Co. stock gains as pipeline and dividend draw fresh investor interest

Merck & Co., Inc. stock (ISIN US58933Y1055) is trading near USD 147 on the New York Stock Exchange as of September 18, 2026, after a recent close of USD 147.17 that marked a gain of about 1.6 percent versus the prior session on September 17, 2026.

Stock holds near the upper end of its 52-week range

For investors, the immediate context for Merck & Co. stock in mid-September 2026 is a resilient share price close to recent highs. According to Yahoo Finance on September 16, 2026, Merck & Co. closed at USD 144.91 per share and has gained 77.74 percent over the past 52 weeks, trading in a range between USD 77.58 and USD 156.92.

Per recent market data compiled by MEXC on September 18, 2026, the stock is quoted around USD 147.15, up 1.55 percent, or USD 2.24, from a previous close of USD 144.91, implying that Merck & Co. stock is now less than USD 10 below its 52-week high of USD 156.92 while more than USD 69 above its 52-week low of USD 77.58.

Pipeline and valuation set the tone

Beyond the price action, Merck & Co. remains defined by its oncology and vaccine pipeline, which continues to attract attention among healthcare investors. As Perplexity Finance noted based on the September 17, 2026 closing data, Merck shares rose 1.56 percent to USD 147.17 as investors rotated back into healthcare amid easing rate-hike concerns and continued enthusiasm for the company’s pipeline beyond Keytruda.

That enthusiasm is tempered by valuation questions. An analysis on September 17, 2026 from GuruFocus argued that Merck & Co. stock looks about 22.4 percent overvalued versus its GF Value estimate of USD 120.14 at a current price of roughly USD 147.05, with a trailing 12-month price-earnings ratio of about 117.55 compared with a five-year median around 20.19.

Dividend yield provides income counterweight

Income-oriented investors are increasingly looking at Merck & Co. dividend metrics as a counterweight to the rich valuation multiples. According to the same GuruFocus analysis dated September 17, 2026, Merck offers a dividend yield of about 2.29 percent with a payout ratio close to 1.05 and dividend growth of roughly 5.4 percent over three years.

This combination means that while the stock trades well above historical earnings multiples, investors still receive more than USD 3 per share annually in cash distributions, and the yield of about 2.3 percent compares with short-term yields in other defensive sectors. For long-term holders, the fact that Merck & Co. dividend has grown in recent years even as the share price advanced more than 70 percent over 12 months is a key part of the investment case.

Short-term performance and sector backdrop

Merck & Co. stock has been part of a broader rebound in large-cap US equities following the latest Federal Reserve rate decision. As Sharecast reported for the US close on September 17, 2026, Merck & Co. finished the session at USD 147.15, up 1.55 percent on the day, moving alongside other Dow Jones constituents in a relief rally as bond yields eased.

A similar picture emerges from Nordic market commentary. A sector overview published by Placera on September 18, 2026 showed Merck quoted at USD 147.15 with a daily change of 1.5 percent and a year-to-date performance of 39.8 percent, underlining that the stock’s strength is not only a one-day move but part of a longer trend.

Closing price and investor takeaway

Based on the latest available closing data from September 17, 2026, Merck & Co. stock ended the regular New York trading session at about USD 147.17, up roughly 1.56 percent from the previous close, with the shares now sitting in the upper segment of their 52-week range between USD 77.58 and USD 156.92. For investors, the combination of strong one-year performance, a dividend yield around 2.3 percent and an elevated valuation multiple makes Merck & Co. a classic case where pipeline progress and cash returns must continue to justify the price.

More news and analyses on Merck & Co. stock